CA3225387A1 - Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising thereof - Google Patents

Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising thereof Download PDF

Info

Publication number
CA3225387A1
CA3225387A1 CA3225387A CA3225387A CA3225387A1 CA 3225387 A1 CA3225387 A1 CA 3225387A1 CA 3225387 A CA3225387 A CA 3225387A CA 3225387 A CA3225387 A CA 3225387A CA 3225387 A1 CA3225387 A1 CA 3225387A1
Authority
CA
Canada
Prior art keywords
seq
peptide
polypeptides
polypeptide
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3225387A
Other languages
English (en)
French (fr)
Inventor
Yordanka Masforrol Gonzalez
Hilda Elisa Garay Perez
Osvaldo Reyes Acosta
Yasser Perera Negrin
Evelin Caballero Menendez
Luis Javier Gonzalez Lopez
Vladimir Armando Besada Perez
Silvio Ernesto Perea Rodriguez
Gerardo Enrique Guillen Nieto
Sonia Gonzalez Blanco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Genetic Engineering and Biotechnology
Original Assignee
Center for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Genetic Engineering and Biotechnology filed Critical Center for Genetic Engineering and Biotechnology
Publication of CA3225387A1 publication Critical patent/CA3225387A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
CA3225387A 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising thereof Pending CA3225387A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2
CU2021-0058 2021-07-09
PCT/CU2022/050007 WO2023280330A1 (es) 2021-07-09 2022-07-07 Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Publications (1)

Publication Number Publication Date
CA3225387A1 true CA3225387A1 (en) 2023-01-12

Family

ID=83080989

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3225387A Pending CA3225387A1 (en) 2021-07-09 2022-07-07 Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising thereof

Country Status (11)

Country Link
US (1) US20240317827A1 (enExample)
EP (1) EP4368710A1 (enExample)
JP (1) JP2024534231A (enExample)
KR (1) KR20240032882A (enExample)
CN (1) CN117795064A (enExample)
AR (1) AR126388A1 (enExample)
AU (1) AU2022308094A1 (enExample)
CA (1) CA3225387A1 (enExample)
CU (1) CU24766B1 (enExample)
MX (1) MX2024000542A (enExample)
WO (1) WO2023280330A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118290537B (zh) * 2024-05-09 2025-02-07 永州中古生物技术有限公司 一种在nci-h460细胞系中对ck2起到抑制作用的多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
WO2006020207A2 (en) * 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
EP2116603A3 (en) * 2004-11-12 2010-02-17 The University Of British Columbia Antimicrobial peptides

Also Published As

Publication number Publication date
CU20210058A7 (es) 2023-02-13
JP2024534231A (ja) 2024-09-18
EP4368710A1 (en) 2024-05-15
AR126388A1 (es) 2023-10-11
WO2023280330A1 (es) 2023-01-12
CU24766B1 (es) 2025-08-13
AU2022308094A1 (en) 2024-02-01
KR20240032882A (ko) 2024-03-12
CN117795064A (zh) 2024-03-29
US20240317827A1 (en) 2024-09-26
MX2024000542A (es) 2024-02-02

Similar Documents

Publication Publication Date Title
US8765909B2 (en) Metastin derivatives and use thereof
AU2013221432B2 (en) Peptidomimetic macrocycles
US20010018511A1 (en) Inhibitors of the interaction between p53 and mdm2
CA2473032A1 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
TW201326200A (zh) 擬肽巨環化合物
ES2375038T3 (es) Derivados de metastina y su uso.
EP3559020B1 (en) New stapled-peptides and uses thereof
CN111690041B (zh) 一类具有抗肿瘤活性多肽及其制备方法
WO2015022283A1 (en) Yap-tead inhibitors
JPH06116284A (ja) 新規ペプチド
JP2001103993A (ja) 環状ペプチド及びセリンプロテアーゼ阻害剤
US20240317827A1 (en) Linear peptides inhibiting ck2-mediated phosphorylation and compositions comprising same
CN111662363A (zh) 环肽类抗肿瘤活性化合物及其制备方法与应用
US20090093615A1 (en) Metastin derivatives and use thereof
US6337385B1 (en) Staphylococcus peptides for bacterial interference
US8697651B2 (en) Amyloid β fibrillogenesis-inhibiting peptide
WO2000073326A2 (en) Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use
US20020142966A1 (en) Inhibitors of the E2F-1/cyclin interaction for cancer therapy
CN115340594A (zh) 一种抑制破骨细胞分化的订书肽及其制备方法和应用
CN115160406A (zh) 一类新型抗肿瘤环肽活性分子的制备方法与应用
AU2023374544A1 (en) Ccr2 inhibitors and methods of use
WO2025186255A1 (en) Gipr inhibitors and methods of use
US20250282824A1 (en) Inhibitors of the Wnt Signaling Pathway and Uses Thereof
WO2025043696A1 (zh) 抗病毒多肽类似物
Varese Approaches to the synthesis of cyclic peptides with inhibitory activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240212

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250512

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250512

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250704

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260708